SBIR: Novel Product Formulation to Modulate Alpha7 Nicotinic Receptors for Therapy in Stroke

Grants and Contracts Details

StatusActive
Effective start/end date7/29/245/31/25

Funding

  • Epigen Biosciences Incorporated: $151,891.00